Asset Details
Do you wish to reserve the book?
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
Do you wish to request the book?
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
2007
Overview
The long-acting factor X inhibitor idraparinux was compared with a standard antithrombotic regimen in two randomized trials, one for the treatment of deep venous thrombosis (DVT Study) and the other for the treatment of pulmonary embolism (PE Study). In the DVT Study, idraparinux was not inferior to standard therapy. In the PE Study, idraparinux was less efficacious than standard therapy.
For the treatment of deep venous thrombosis, idraparinux was not inferior to standard therapy. For the treatment of pulmonary embolism, idraparinux was less efficacious than standard therapy.
The standard treatment for both deep venous thrombosis and pulmonary embolism is an initial course of unfractionated heparin or low-molecular-weight heparin, followed by a vitamin K antagonist for 3 to 12 months.
1
,
2
This therapy is effective but requires laboratory monitoring and dose adjustments. Idraparinux (Sanofi-Aventis) is a novel synthetic pentasaccharide that inhibits activated factor X and differs from fondaparinux in its substantially longer half-life. Initial clinical experience suggests that a fixed dose given subcutaneously once weekly is effective and causes less bleeding than vitamin K antagonists in the treatment of venous thromboembolism.
3
,
4
In two studies in patients presenting . . .
Publisher
Massachusetts Medical Society
Subject
/ Anticoagulants - adverse effects
/ Anticoagulants - therapeutic use
/ Biological and medical sciences
/ Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
/ Female
/ Hemorrhage - chemically induced
/ Heparin
/ Humans
/ Male
/ Oligosaccharides - adverse effects
/ Oligosaccharides - therapeutic use
/ Pulmonary Embolism - drug therapy
/ Pulmonary Embolism - mortality
/ Venous Thrombosis - drug therapy
